Loss-of-function mutations in the histone methyltransferase EZH2 promote chemotherapy resistance in AML

Chemotherapy resistance is the main impediment in the treatment of acute myeloid leukaemia (AML). Despite rapid advances, the various mechanisms inducing resistance development remain to be defined in detail. Here we report that loss-of-function mutations (LOF) in the histone methyltransferase EZH2...

Descripción completa

Detalles Bibliográficos
Autores principales: Kempf, Julia M., Weser, Sabrina, Bartoschek, Michael D., Metzeler, Klaus H., Vick, Binje, Herold, Tobias, Völse, Kerstin, Mattes, Raphael, Scholz, Manuela, Wange, Lucas E., Festini, Moreno, Ugur, Enes, Roas, Maike, Weigert, Oliver, Bultmann, Sebastian, Leonhardt, Heinrich, Schotta, Gunnar, Hiddemann, Wolfgang, Jeremias, Irmela, Spiekermann, Karsten
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955088/
https://www.ncbi.nlm.nih.gov/pubmed/33712646
http://dx.doi.org/10.1038/s41598-021-84708-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7955088/
https://www.ncbi.nlm.nih.gov/pubmed/33712646
http://dx.doi.org/10.1038/s41598-021-84708-6

Ejemplares similares